| pubmed-article:9259533 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0599779 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0262950 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0391978 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0012544 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0221198 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0851346 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C0750572 | lld:lifeskim |
| pubmed-article:9259533 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9259533 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9259533 | pubmed:dateCreated | 1997-9-30 | lld:pubmed |
| pubmed-article:9259533 | pubmed:abstractText | A common complication in patients with breast or prostate cancer is bone metastases causing pain. New radionuclide therapy methods have recently been proposed for palliation, including 186Re-hydroxyethylidene diphosphonate (186Re-HEDP). This paper reports on the local development of 186Re-HEDP and the biodistribution studied in animals for eventual use in patients. Adult dose was computed assuming a 70 kg standard man. The 186Re was labelled to HEDP using standard techniques. The biodistribution in five Chacma baboons (Papio ursinus) was studied. Doses ranging from 39.4 to 44.9 MBq kg(-1) (mean 43.6 +/- 2.8 MBq kg[-1]) were administered, corresponding to an adult human dose of 2960 MBq (80 mCi). Whole-body images of the animals were obtained with a dual-headed scintillation camera on an hourly basis for 6 h post-injection and then daily for 3 days. The bone, soft tissue, kidneys and urinary bladder were considered source organs and data from these organs were used in a compartmental model to obtain the mean residence times of the radionuclide in the different source organs. Radiation dose estimates for 186Re-HEDP were subsequently obtained with the MIRDOSE 3 program. The estimated absorbed radiation doses to some of the organs (expressed in mGy MBq[-l]) were as follows: bone surface 1.69; kidneys 0.09; liver 0.04; ovaries 0.04; red marrow 0.75; total body 0.12; urinary bladder wall 0.43. 186Re-HEDP yielded an effective dose of 0.17 mSv MBq(-1). The radiation dose delivered to the bone marrow in this study did not cause any detrimental effect to the baboons, indicating that locally produced 186Re-HEDP is suitable for clinical use. | lld:pubmed |
| pubmed-article:9259533 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9259533 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9259533 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9259533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9259533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9259533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9259533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9259533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9259533 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9259533 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9259533 | pubmed:issn | 0143-3636 | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:DoschH MHM | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:LötterM GMG | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:van AswegenAA | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:OttoA CAC | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:GoedhalsLL | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:MaraisJJ | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:NaudéHH | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:BothaJ MJM | lld:pubmed |
| pubmed-article:9259533 | pubmed:author | pubmed-author:RoodtAA | lld:pubmed |
| pubmed-article:9259533 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9259533 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:9259533 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9259533 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9259533 | pubmed:pagination | 582-8 | lld:pubmed |
| pubmed-article:9259533 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:meshHeading | pubmed-meshheading:9259533-... | lld:pubmed |
| pubmed-article:9259533 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9259533 | pubmed:articleTitle | Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study. | lld:pubmed |
| pubmed-article:9259533 | pubmed:affiliation | Department of Biophysics, University of the Orange Free State, Bloemfontein, South Africa. | lld:pubmed |
| pubmed-article:9259533 | pubmed:publicationType | Journal Article | lld:pubmed |
